| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:23 | Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) | Unclassified | WPHA/WNT Endorsed | Pimephales promelas | 0.2 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | Fathead minnow, Medaka, Zebrafish | 0.25 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:112 | Increased dopaminergic activity leading to endometrial adenocarcinomas (in Wistar rat) | Reproductive system disease; Cancer | - | Rattus norvegicus | 0.17 | KE:749 | Decreased, Progesterone from corpus luteum |
| AOP:120 | Inhibition of 5α-reductase leading to Leydig cell tumors (in rat) | Cancer; Reproductive system disease | - | Rattus norvegicus, Mus musculus | 0.2 | KE:1690 | Decrease, circulating testosterone levels |
| AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | Pimephales promelas | 0.2 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | Pimephales promelas | 0.18 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | Fish | 0.2 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| AOP:274 | Histone deacetylase inhibition leads to impeded craniofacial development | Musculoskeletal system disease | - | 0.25 | KE:1558 | Collagen production, reduced | |
| AOP:288 | Inhibition of 17α-hydrolase/C 10,20-lyase (Cyp17A1) activity leads to birth reproductive defects (cryptorchidism) in male (mammals) | Endocrine system disease | - | Human, Rat | 0.12 | KE:1690 | Decrease, circulating testosterone levels |
| AOP:289 | Inhibition of 5α-reductase leading to impaired fecundity in female fish | Unclassified | Under Development | Fish | 0.17 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| AOP:309 | Luteinizing hormone receptor antagonism leading to reproductive dysfunction | Unclassified | - | Fish | 0.29 | KE:1693 | Reduction, Plasma progesterone concentration |
| KE:1692 | Reduction, Progesterone synthesis | ||||||
| AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | Zebrafish | 0.17 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | Zebrafish, Oreochromis niloticus, Chinook salmon, Fathead minnow, European sea bass | 0.2 | KE:1789 | Reduction, 17beta-estradiol synthesis by the undifferentiated gonad |
| AOP:348 | Inhibition of 11β-Hydroxysteroid Dehydrogenase leading to decreased population trajectory | Unclassified | Under Development | Fish | 0.2 | KE:406 | decreased, Fertility |
| AOP:349 | Inhibition of 11β-hydroxylase leading to decresed population trajectory | Unclassified | Under Development | Fish | 0.12 | KE:406 | decreased, Fertility |
| AOP:496 | Androgen receptor agonism leading to reproduction dysfunction (in zebrafish) | Unclassified | - | Zebrafish | 0.2 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:1690 | Decrease, circulating testosterone levels | ||||||
| AOP:504 | SULT1E1 inhibition leading to uterine adenocarcinoma via increased estrogen availability at target organ level | Unclassified | - | Mammals | 0.33 | KE:2251 | Estradiol availability, increased |
| AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | Murinae gen. sp. | 0.14 | KE:2206 | Increased, histomorphological alteration of testis |
| AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental disorder of mental health | - | Mouse, Human | 0.11 | KE:2233 | Decreased, ERαβ heterodimers |
| AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.11 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | |
| AOP:549 | Aromatase inhibition leads to reproductive toxicity (including growth and developmental toxicity) in adult female zebrafish | Unclassified | - | 0.12 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations | |
| AOP:561 | Aromatase induction leading to estrogen receptor alpha activation via increased estradiol | Unclassified | - | Vertebrates | 0.4 | KE:2294 | Plasma estradiol, increased |
| KE:2251 | Estradiol availability, increased |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | Mus musculus, Homo sapiens, Pimephales promelas, Colinus virginianus, Rattus norvegicus | 0.12 | KE:864 | Decreased, Body Weight |
| AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive system disease; Endocrine system disease; Reproductive system disease | Under Review | Rat, Mouse, Human | 0.6 | KE:219 | Reduction, Plasma 17beta-estradiol concentrations |
| KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells | ||||||
| KE:406 | decreased, Fertility | ||||||
| AOP:18 | PPARα activation in utero leading to impaired fertility in males | Reproductive system disease | Under Review | Human, Rat, Mouse | 0.25 | KE:1690 | Decrease, circulating testosterone levels |
| KE:406 | decreased, Fertility | ||||||
| AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive system disease | - | Rattus norvegicus | 0.29 | KE:1690 | Decrease, circulating testosterone levels |
| KE:406 | decreased, Fertility | ||||||
| AOP:124 | HMG-CoA reductase inhibition leading to decreased fertility | Reproductive system disease | - | Rattus rattus | 0.33 | KE:1690 | Decrease, circulating testosterone levels |
| KE:330 | Decrease, Fertility | ||||||
| AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive system disease | WPHA/WNT Endorsed | Rat, Human, Mouse | 0.17 | KE:1506 | Testicular atrophy |
| AOP:345 | Androgen receptor (AR) antagonism leading to decreased fertility in females | Endocrine system disease; Reproductive system disease; Reproductive system disease | Under Development | Mammals | 0.17 | KE:406 | decreased, Fertility |
| AOP:398 | Decreased ALDH1A (RALDH) activity leading to decreased fertility via disrupted meiotic initiation of fetal oogonia | Reproductive system disease | Under Development | Mouse, Rat, Human | 0.17 | KE:406 | decreased, Fertility |
| AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive system disease | - | Mammals, Fish | 0.2 | KE:406 | decreased, Fertility |
| AOP Identifier | AOP Title | AO Classification | OECD Status | Taxonomic applicability | Coverage Score ⓘ The fraction of KEs within the AOP, that are mapped to the chemical-associated toxicological endpoints. | KE Identifier | KE Name |
|---|---|---|---|---|---|---|---|
| AOP:8 | Upregulation of Thyroid Hormone Catabolism via Activation of Hepatic Nuclear Receptors, and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Nervous system disease | Under Development | Rat | 0.11 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:60 | NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | 0.08 | KE:245 | Activation, PXR/SXR | |
| AOP:517 | Pregnane X Receptor (PXR) activation leads to liver steatosis | Gastrointestinal system disease; Inherited metabolic disorder | - | Vertebrates | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:545 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased cholesterol synthesis | Unclassified | - | Mammals | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
| AOP:548 | Activation, Pregnane-X receptor, NR1l2 leads to increased plasma low-density lipoprotein (LDL) cholesterol via increased PCSK9 protein expression | Unclassified | - | Mammals | 0.2 | KE:239 | Activation, Pregnane-X receptor, NR1l2 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.